CSL 324

Drug Profile

CSL 324

Alternative Names: Anti-CSF3 Therapeutic Antibody; Anti-G-CSFR mAb; CSL324; CSL324 G-CSFR; G-CSF antagonists - CSL

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MuriGen Therapeutics; Zenyth Therapeutics
  • Developer CSL
  • Class Monoclonal antibodies
  • Mechanism of Action Granulocyte colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation; Rheumatoid arthritis

Most Recent Events

  • 30 Jun 2016 Phase-I clinical trials in Inflammation (In volunteers) in Australia (IV) (ACTRN12616000846426)
  • 30 Jun 2016 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Australia (IV) (ACTRN12616000846426)
  • 21 Feb 2006 Preclinical trials in Inflammation in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top